Lixte Biotechnology Holdings is a biotechnology business based in the US. Lixte Biotechnology Holdings shares (LIXT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.92 – an increase of 9.04% over the previous week. Lixte Biotechnology Holdings employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.92 |
|---|---|
| 52-week range | $1.55 - $4.42 |
| 50-day moving average | $1.93 |
| 200-day moving average | $2.37 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.64 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.8899 from 2024-10-18
| 1 week (2024-10-16) | 7.33% |
|---|---|
| 1 month (2024-09-23) | 2.71% |
| 3 months (2024-07-23) | -19.24% |
| 6 months (2024-04-23) | -41.31% |
| 1 year (2023-10-23) | -11.69% |
|---|---|
| 2 years (2022-10-21) | 263.44% |
| 3 years (2021-10-22) | 1.06% |
| 5 years (2019-10-22) | 7.74 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -87.33% |
| Return on equity TTM | -163.33% |
| Profit margin | 0% |
| Book value | $-0.56 |
| Market Capitalization | $4.2 million |
TTM: trailing 12 months
We're not expecting Lixte Biotechnology Holdings to pay a dividend over the next 12 months.
You may also wish to consider:
Lixte Biotechnology Holdings's shares were split on a 1:10 basis on 4 June 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lixte Biotechnology Holdings shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Lixte Biotechnology Holdings shares which in turn could have impacted Lixte Biotechnology Holdings's share price.
Over the last 12 months, Lixte Biotechnology Holdings's shares have ranged in value from as little as $1.55 up to $4.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lixte Biotechnology Holdings's is -0.155. This would suggest that Lixte Biotechnology Holdings's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lixte Biotechnology Holdings has bucked the trend.
To put Lixte Biotechnology Holdings's beta into context you can compare it against those of similar companies.
LIXTE Biotechnology Holdings, Inc. , a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.